Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Sanford-Burnham scientists show that coupling a tumor-homing peptide and an anti-cancer drug drastically reduces tumors in a mouse model of colon cancer, with no apparent side effects; technique could be applied to many types of cancer
LA JOLLA, Calif., November 21, 2011 - The trouble with most anti-cancer therapies is that they are lethal to most cells in the body, not just cancer cells. As a result, patients experience side effects like nausea, increased susceptibility to infection, and increased risk of developing secondary cancers later in life. Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) are developing techniques to deliver cancer drugs directly to tumors, increasing their effectiveness and decreasing collateral damage. In a study published the week of November 21 in the Proceedings of the National Academy of Sciences of the USA, a team led by Michiko Fukuda, Ph.D. coupled a cancer drug to a small protein called IF7, which is specifically attracted to the blood vessels that feed tumors. When administered in a mouse model of human colon cancer, IF7 carried the drug directly to tumors, where it suppressed growth at low dosages and with no apparent side effects. These findings suggest that IF7 is an efficient drug delivery vehicle that could be further exploited to target a variety of anti-cancer therapeutics where they're needed most, without harming other tissues.
"We can cure terminal stage mice with very large tumors without any side effects simply by giving them this drug coupled with IF7," said Dr. Fukuda, professor in Sanford-Burnham's National Cancer Institute (NCI)-designated Cancer Center and corresponding author of the study.
Carbohydrates coat the surface of every cell in the body. They-and the proteins that bind them-play important roles in many cellular processes, including tumor formation and cancer metastasis. However, unlike genes or proteins, carbohydrates are difficult to synthesize in the lab. To get around that hurdle, Dr. Fukuda and her team tested a collection of short proteins (called peptides) in the hopes of finding some that can mimic carbohydrates and inhibit carbohydrate-dependent metastasis. IF7 was one of the "winning" peptides. Upon further investigation, Dr. Fukuda's team found that IF7 works because it binds annexin 1, a carbohydrate-binding protein that is found in particularly high levels on the surfaces of blood vessels that feed tumors.
In this study, the researchers coupled IF7 with a fluorescent probe and administered it to mice bearing human colon tumors. They watched as, within minutes, the probe lit up the tumors. Next, they coupled IF7 with SN-38, a potent anti-cancer drug. They also engineered the tumors to glow, so they could measure them after daily injections with IF7/SN-38. Tumors in treated mice shrank dramatically while tumor size in mock-treated mice was unchanged. It's worth noting that the amount of SN-38 the mice received in this study was only one-seventh the amount a previous study used to treat tumors in mice. Perhaps for that reason, blood tests showed no signs of side effects in IF7/SN-38-treated mice.
"Although we tested colon tumors in this study, theoretically any tumor that induces expression of annexin 1 in blood vessels would work with this system-it just depends on what kind of drug it's paired with," said Minoru Fukuda, Ph.D., professor in Sanford-Burnham's National Cancer Institute (NCI)-designated Cancer Center and co-author of the study.
Given its extremely specific tumor-targeting activity, the authors conclude that IF7 may represent a clinically relevant vehicle for anti-cancer drugs. Next, they hope to further prepare this technology for clinical trials in humans.
This research was funded by the National Cancer Institute, part of the National Institutes of Health, the Department of Defense, and Susan G. Komen for the Cure. Co-authors include Shingo Hatakeyama, Sanford-Burnham; Kazuhiro Sugihara, Hamamatsu University School of Medicine; Toshiaki K. Shibata, Sanford-Burnham; Jun Nakayama, Shinshu University Graduate School of Medicine; Tomoya O. Akama, Sanford-Burnham; Naoaki Tamura, Sanford-Burnham; Shuk-Man Wong, Sanford-Burnham; Andrey A. Bobkov, Sanford-Burnham; Yutaka Takano, Sanford-Burnham; Chikara Ohyama, Hirosaki University School of Medicine; Minoru Fukuda, Sanford-Burnham; and Michiko N. Fukuda, Sanford-Burnham.
For more information about Sanford-Burnham research, visit our blog or follow us on Twitter.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The Institute ranks among the top independent research institutions nationally for NIH grant funding and among the top organizations worldwide for its research impact. From 1999 - 2009, Sanford-Burnham ranked #1 worldwide among all types of organizations in the fields of biology and biochemistry for the impact of its research publications, defined by citations per publication, according to the Institute for Scientific Information. According to government statistics, Sanford-Burnham ranks #2 nationally among all organizations in capital efficiency of generating patents, defined by the number of patents issued per grant dollars awarded.
Sanford-Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Sanford-Burnham is a nonprofit public benefit corporation. For more information, please visit www.sanfordburnham.org.